Clopidogrel versus aspirin for coronary artery disease.

This study aimed to compare the efficacy and safety of clopidogrel versus aspirin in patients with coronary artery disease. Key findings demonstrated that clopidogrel was superior to aspirin in reducing ischemic events, including myocardial infarction, stroke, or cardiovascular death, with a comparable safety profile regarding major bleeding. These results suggest that clopidogrel may be a more effective antiplatelet therapy than aspirin for secondary prevention in a broad range of CAD patients, potentially impacting clinical guidelines for antiplatelet selection.